B. Riley has lowered its price target for Novavax (NVAX) from $18 to $16, while reiterating a 'Buy' rating. This adjustment follows the company's third-quarter 2026 financial results, suggesting a re-evaluation of future growth prospects or valuation metrics by the analyst.
B. Riley's decision to lower Novavax's price target from $18 to $16, despite maintaining a 'Buy' rating, indicates a nuanced view of the company's future. This adjustment likely stems from the recently released Q3 2026 financial results, which may have presented a less optimistic outlook than previously anticipated, or perhaps a recalibration of valuation models. For traders, this could signal a short-term negative sentiment as the lowered price target might temper enthusiasm, even with the 'Buy' rating. However, the continued 'Buy' rating suggests that B. Riley still sees long-term upside potential, albeit at a slightly reduced valuation. The key risk for traders is potential downward pressure on the stock in the immediate term, while the opportunity lies in identifying if the market overreacts to the price target cut, creating a buying opportunity for those who align with B. Riley's long-term positive outlook.